DEXCOM INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.7B | $4.0B | $3.6B | $2.9B | $2.4B |
| Gross profit | $2.8B | $2.4B | $2.3B | $1.9B | $1.7B |
| Operating income | $911.8M | $600.0M | $597.7M | $391.2M | $265.8M |
| Operating expenses | $1.9B | $1.8B | $1.7B | $1.5B | $1.4B |
| Cost of revenue | $1.9B | $1.6B | $1.3B | $1.0B | $768.0M |
| Cash from operations | $1.4B | $989.5M | $748.5M | $669.5M | $442.5M |
| Capital expenditure | $363.5M | $358.8M | $236.6M | $364.8M | $389.2M |
| Free cash flow | $1.1B | $630.7M | $511.9M | $304.7M | $53.3M |
| Share repurchases | $500.0M | $750.0M | $688.7M | $557.7M | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $6.3B | $6.5B | $6.3B | $5.4B | $4.9B |
| Total liabilities | $3.6B | $4.4B | $4.2B | $3.3B | $2.9B |
Shares outstanding 385.9M · Free float 99.5%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.